|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000178372 |
Summary for CALML5 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000178372 | Gene symbol | CALML5 |
| Gene name | calmodulin like 5 | |
| HGNC | 18180 | |
| Entrez ID | 51806 | |
| Gene type | protein_coding | |
| Synonyms | CALML5|CLSP | |
| UniProtAcc | Q9NZT1 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for CALML5 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CALML5 | 5.00e+03 | -5.41e+00 | 8.46e-01 | -6.39e+00 | 1.65e-10 | 6.41e-08 | BRCA |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CALML5 | 1.99e+03 | 7.22e+00 | 1.11e+00 | 6.49e+00 | 8.58e-11 | 1.84e-09 | BLCA |
| CALML5 | 2.01e+03 | 4.73e+00 | 1.14e+00 | 4.14e+00 | 3.49e-05 | 4.26e-04 | ESCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CALML5 | 4.65e+03 | 2.99e+00 | 2.84e-01 | 1.05e+01 | 7.22e-26 | 3.11e-25 | BRCA |
Top |
Sex-biased somatic mutation for CALML5 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for CALML5 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg16048771 | chr10:5499183 | CGI:chr10:5498822-5499552 | promoter,exon,CDS,gene body | 8.08e-01 | 9.15e-01 | -1.98e+00 | 4.77e-02 | 4.91e-02 | -1.07e-01 |
| BRCA | cg14096855 | chr10:5499860 | CGI:chr10:5498822-5499552 | promoter | 6.28e-01 | 7.47e-01 | -2.58e+00 | 9.96e-03 | 2.66e-02 | -1.19e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| HNSC | cg23625250 | chr10:5498861 | CGI:chr10:5498822-5499552 | UTR,promoter,exon,gene body | 7.83e-01 | 9.20e-01 | -2.79e+00 | 5.29e-03 | 7.46e-03 | -1.38e-01 |
| LUSC | cg02382706 | chr10:5498704 | CGI:chr10:5498822-5499552 | UTR,promoter,exon,gene body | 8.00e-01 | 9.13e-01 | -3.26e+00 | 1.10e-03 | 2.76e-03 | -1.13e-01 |
| LUSC | cg00797152 | chr10:5499605 | CGI:chr10:5498822-5499552 | promoter | 5.04e-01 | 7.47e-01 | -4.08e+00 | 4.43e-05 | 5.44e-04 | -2.43e-01 |
| LUSC | cg02754943 | chr10:5499755 | CGI:chr10:5498822-5499552 | promoter | 5.24e-01 | 7.05e-01 | -4.25e+00 | 2.15e-05 | 5.26e-04 | -1.82e-01 |
| LUSC | cg17278890 | chr10:5499763 | CGI:chr10:5498822-5499552 | promoter | 6.85e-01 | 8.96e-01 | -4.04e+00 | 5.42e-05 | 5.68e-04 | -2.11e-01 |
| LUSC | cg14096855 | chr10:5499860 | CGI:chr10:5498822-5499552 | promoter | 7.02e-01 | 8.40e-01 | -3.71e+00 | 2.06e-04 | 9.85e-04 | -1.38e-01 |
| BLCA | cg17278890 | chr10:5499763 | CGI:chr10:5498822-5499552 | promoter | 6.44e-01 | 8.11e-01 | -3.27e+00 | 1.08e-03 | 2.41e-03 | -1.67e-01 |
| BLCA | cg14096855 | chr10:5499860 | CGI:chr10:5498822-5499552 | promoter | 7.15e-01 | 8.38e-01 | -3.47e+00 | 5.20e-04 | 1.37e-03 | -1.23e-01 |
| LIHC | cg21130124 | chr10:5500365 | CGI:chr10:5498822-5499552 | promoter | 7.86e-01 | 9.13e-01 | -5.31e+00 | 1.07e-07 | 5.59e-07 | -1.27e-01 |
| KIRP | cg00797152 | chr10:5499605 | CGI:chr10:5498822-5499552 | promoter | 8.35e-01 | 7.00e-01 | 5.56e+00 | 2.75e-08 | 3.11e-07 | 1.35e-01 |
| CHOL | cg00797152 | chr10:5499605 | CGI:chr10:5498822-5499552 | promoter | 7.27e-01 | 8.57e-01 | -2.43e+00 | 1.50e-02 | 2.65e-02 | -1.30e-01 |
| CHOL | cg02754943 | chr10:5499755 | CGI:chr10:5498822-5499552 | promoter | 6.09e-01 | 7.48e-01 | -2.88e+00 | 4.04e-03 | 1.47e-02 | -1.38e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg00797152 | chr10:5499605 | CGI:chr10:5498822-5499552 | promoter | 4.10e-01 | 5.56e-01 | -9.63e+00 | 6.19e-22 | 3.96e-21 | -1.46e-01 |
| BRCA | cg02754943 | chr10:5499755 | CGI:chr10:5498822-5499552 | promoter | 4.51e-01 | 5.95e-01 | -1.21e+01 | 1.48e-33 | 3.47e-32 | -1.44e-01 |
| BRCA | cg17278890 | chr10:5499763 | CGI:chr10:5498822-5499552 | promoter | 5.90e-01 | 7.24e-01 | -8.34e+00 | 7.72e-17 | 3.24e-16 | -1.35e-01 |
| BRCA | cg14096855 | chr10:5499860 | CGI:chr10:5498822-5499552 | promoter | 6.28e-01 | 7.46e-01 | -7.49e+00 | 6.81e-14 | 2.28e-13 | -1.18e-01 |
| HNSC | cg00797152 | chr10:5499605 | CGI:chr10:5498822-5499552 | promoter | 4.59e-01 | 3.46e-01 | 2.00e+00 | 4.53e-02 | 4.65e-02 | 1.13e-01 |
| HNSC | cg17278890 | chr10:5499763 | CGI:chr10:5498822-5499552 | promoter | 6.24e-01 | 5.01e-01 | 2.23e+00 | 2.59e-02 | 3.23e-02 | 1.23e-01 |
Top |
Exon skipping events with PSI in TCGA for CALML5 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for CALML5 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for CALML5 |
| TFs related to CALML5. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| DLBC | ZNF181 | CALML5 | 4.27e+00 | 9.89e-01 | 2.84e+00 | 1.12e-03 | Male-biased |
| DLBC | ZNF519 | CALML5 | 4.17e+00 | 9.86e-01 | 2.87e+00 | 1.79e-03 | Male-biased |
| DLBC | ZNF571 | CALML5 | 4.33e+00 | 9.89e-01 | 2.98e+00 | 1.52e-03 | Male-biased |
| DLBC | ZNF770 | CALML5 | 4.32e+00 | 9.89e-01 | 2.97e+00 | 1.48e-03 | Male-biased |
| DLBC | ZNF774 | CALML5 | 4.18e+00 | 9.86e-01 | 2.96e+00 | 2.44e-03 | Male-biased |
| CALML5 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for CALML5 |
| RBPs related to ES in CALML5. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| CALML5 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs10905390 | chr10:8495732:A:G | - | 0.130093243311113 | 0.00424034808031664 | LUSC | Female-baised eQTL |
| rs2439909 | chr10:6787139:G:T | - | -0.0938825466250029 | 0.00343730738608206 | STAD | Female-baised eQTL |
| rs2439908 | chr10:6787568:A:G | - | -0.0938825466250029 | 0.00343730738608206 | STAD | Female-baised eQTL |
| rs2501696 | chr10:6790245:T:A | - | -0.0938825466250029 | 0.00343730738608206 | STAD | Female-baised eQTL |
| rs61830472 | chr10:3404473:A:G | - | 0.0862826964543265 | 0.015575277175287 | STAD | Female-baised eQTL |
| rs11251881 | chr10:3420839:G:C | - | 0.0862826964543265 | 0.015575277175287 | STAD | Female-baised eQTL |
| rs11251885 | chr10:3437971:T:A | - | 0.0863095904277787 | 0.0156350825594319 | STAD | Female-baised eQTL |
| rs12261202 | chr10:3375220:C:A | - | 0.080149567524352 | 0.0297745788470125 | STAD | Female-baised eQTL |
| rs17135199 | chr10:3391563:A:G | - | 0.0802684041521446 | 0.0299575442391116 | STAD | Female-baised eQTL |
| rs945799 | chr10:3396143:A:G | - | -0.0803321304461487 | 0.0301833036591027 | STAD | Female-baised eQTL |
| rs4373823 | chr10:3398969:T:A | - | -0.0802686823663303 | 0.030222172164282 | STAD | Female-baised eQTL |
| rs7085235 | chr10:3399498:C:T | - | -0.0802686823663303 | 0.030222172164282 | STAD | Female-baised eQTL |
| rs6602191 | chr10:6769443:G:T | - | 0.0746405554099451 | 0.0329265968747407 | STAD | Female-baised eQTL |
| rs61830473 | chr10:3410353:C:T | - | 0.0753126393313356 | 0.0474543968428339 | STAD | Female-baised eQTL |
| rs74416796 | chr10:11047491:C:T | - | 0.133145471998792 | 0.0492577906265304 | STAD | Female-baised eQTL |
| rs192697783 | chr10:6800512:T:C | - | 0.139782434471303 | 0.000674368620805198 | BLCA | Female-baised eQTL |
| rs112393198 | chr10:6801858:G:A | - | 0.139654299171486 | 0.000683867212119107 | BLCA | Female-baised eQTL |
| rs11254718 | chr10:6802593:G:A | - | 0.139654299171486 | 0.000683867212119107 | BLCA | Female-baised eQTL |
| rs10904987 | chr10:6802918:T:G | - | 0.139654299171486 | 0.000683867212119107 | BLCA | Female-baised eQTL |
| rs10904988 | chr10:6802922:C:T | - | 0.139654299171486 | 0.000683867212119107 | BLCA | Female-baised eQTL |
| rs12412932 | chr10:14071283:T:C | - | 0.14324664991597 | 0.00108852410822771 | BLCA | Female-baised eQTL |
| rs7070908 | chr10:12625195:G:A | - | 0.118079930293602 | 0.004799534999531 | BLCA | Female-baised eQTL |
| rs11257921 | chr10:12625875:A:G | - | 0.118079930293602 | 0.004799534999531 | BLCA | Female-baised eQTL |
| rs72771756 | chr10:12631937:G:C | - | 0.118079930293602 | 0.004799534999531 | BLCA | Female-baised eQTL |
| rs7897208 | chr10:12632545:C:G | - | 0.118079930293602 | 0.004799534999531 | BLCA | Female-baised eQTL |
| rs11254690 | chr10:6797287:G:A | - | 0.116642398123272 | 0.00669682954761096 | BLCA | Female-baised eQTL |
| rs73573548 | chr10:12004248:A:G | - | 0.122204225799053 | 0.00695942674203252 | BLCA | Female-baised eQTL |
| rs7913028 | chr10:12005632:A:G | - | 0.122204225799053 | 0.00695942674203252 | BLCA | Female-baised eQTL |
| rs57280404 | chr10:12005735:C:A | - | 0.122204225799053 | 0.00695942674203252 | BLCA | Female-baised eQTL |
| rs11812638 | chr10:12006053:C:T | - | 0.122204225799053 | 0.00695942674203252 | BLCA | Female-baised eQTL |
| rs11594545 | chr10:12006775:A:G | - | 0.122204225799053 | 0.00695942674203252 | BLCA | Female-baised eQTL |
| rs187998580 | chr10:6800544:A:G | - | 0.116483924331754 | 0.0070215139494606 | BLCA | Female-baised eQTL |
| rs11254706 | chr10:6801328:A:G | - | 0.105966511871809 | 0.0162632931353006 | BLCA | Female-baised eQTL |
| rs78706219 | chr10:6801705:G:A | - | 0.105966511871809 | 0.0162632931353006 | BLCA | Female-baised eQTL |
| rs141733899 | chr10:6801767:G:C | - | 0.105966511871809 | 0.0162632931353006 | BLCA | Female-baised eQTL |
| rs200319199 | chr10:6802111:G:T | - | 0.105966511871809 | 0.0162632931353006 | BLCA | Female-baised eQTL |
| rs201118935 | chr10:6802112:T:A | - | 0.105966511871809 | 0.0162632931353006 | BLCA | Female-baised eQTL |
| rs4405215 | chr10:12328594:G:C | - | 0.0920502977560683 | 0.0182920789470983 | BLCA | Female-baised eQTL |
| rs370659568 | chr10:6800010:A:G | - | 0.098595639689327 | 0.0216051963044098 | BLCA | Female-baised eQTL |
| rs72775910 | chr10:11867402:C:T | - | 0.0870485887856107 | 0.0354756918371169 | BLCA | Female-baised eQTL |
| rs72775912 | chr10:11867492:C:T | - | 0.0870485887856107 | 0.0354756918371169 | BLCA | Female-baised eQTL |
| rs72775940 | chr10:11882218:T:C | - | 0.0862849989085956 | 0.0390525387747137 | BLCA | Female-baised eQTL |
| rs72775943 | chr10:11882874:G:A | - | 0.0862849989085956 | 0.0390525387747137 | BLCA | Female-baised eQTL |
| rs72775944 | chr10:11883055:T:C | - | 0.0862849989085956 | 0.0390525387747137 | BLCA | Female-baised eQTL |
| rs12416669 | chr10:11853325:C:T | - | 0.0862906289291807 | 0.0394664004059363 | BLCA | Female-baised eQTL |
| rs145759608 | chr10:11860570:G:A | - | 0.0862906289291807 | 0.0394664004059363 | BLCA | Female-baised eQTL |
| rs72774089 | chr10:11860639:G:T | - | 0.0862906289291807 | 0.0394664004059363 | BLCA | Female-baised eQTL |
| rs74657303 | chr10:11870229:G:A | - | 0.0862822922294537 | 0.0395101085415548 | BLCA | Female-baised eQTL |
| rs41291265 | chr10:11871388:A:G | - | 0.0862822922294537 | 0.0395101085415548 | BLCA | Female-baised eQTL |
| rs10905021 | chr10:6818415:T:C | - | 0.0909103600473757 | 0.0405659765034035 | BLCA | Female-baised eQTL |
| rs6602745 | chr10:6494590:C:T | - | 0.100791015065604 | 0.0406378420023955 | BLCA | Female-baised eQTL |
| rs7904257 | chr10:5838525:G:T | - | 0.0902767375135586 | 0.0414950292804303 | BLCA | Female-baised eQTL |
| rs77476954 | chr10:8896598:A:G | - | 0.088990192725506 | 0.0425666717751078 | BLCA | Female-baised eQTL |
| rs78539108 | chr10:8897235:A:T | - | 0.088990192725506 | 0.0425666717751078 | BLCA | Female-baised eQTL |
| rs76407406 | chr10:8902089:A:G | - | 0.088990192725506 | 0.0425666717751078 | BLCA | Female-baised eQTL |
| rs79186901 | chr10:8905645:T:C | - | 0.088990192725506 | 0.0425666717751078 | BLCA | Female-baised eQTL |
| rs17413004 | chr10:8907217:T:A | - | 0.088990192725506 | 0.0425666717751078 | BLCA | Female-baised eQTL |
| rs75375842 | chr10:8909066:C:A | - | 0.088990192725506 | 0.0425666717751078 | BLCA | Female-baised eQTL |
| rs17413266 | chr10:8910589:C:T | - | 0.088990192725506 | 0.0425666717751078 | BLCA | Female-baised eQTL |
| rs74319752 | chr10:8912487:T:C | - | 0.088990192725506 | 0.0425666717751078 | BLCA | Female-baised eQTL |
| rs76141549 | chr10:8898991:G:A | - | 0.088967035229026 | 0.0429943928813387 | BLCA | Female-baised eQTL |
| rs78400042 | chr10:8892059:T:G | - | 0.088966772340146 | 0.0429960881288984 | BLCA | Female-baised eQTL |
| rs76718063 | chr10:8892817:G:T | - | 0.088966772340146 | 0.0429960881288984 | BLCA | Female-baised eQTL |
| rs77097907 | chr10:8904507:C:A | - | 0.0888590121513998 | 0.0436160708823378 | BLCA | Female-baised eQTL |
| rs76897879 | chr10:590404:C:T | - | 0.100464425517767 | 0.000476668183588895 | LUAD | Female-baised eQTL |
| rs11252981 | chr10:524844:C:G | - | 0.0927975834813556 | 0.00123905450747837 | LUAD | Female-baised eQTL |
| rs11253246 | chr10:570670:C:T | - | 0.0927731262752096 | 0.0012494190208442 | LUAD | Female-baised eQTL |
| rs11253255 | chr10:577146:G:A | - | 0.0927731262752096 | 0.0012494190208442 | LUAD | Female-baised eQTL |
| rs78706681 | chr10:550999:G:A | - | 0.0892186900876524 | 0.00194848381279692 | LUAD | Female-baised eQTL |
| rs11253134 | chr10:549533:C:T | - | 0.0891946469530266 | 0.00196401946316384 | LUAD | Female-baised eQTL |
| rs35190859 | chr10:7422131:G:A | - | 0.0663988156767799 | 0.00322708347309925 | LUAD | Female-baised eQTL |
| rs71481723 | chr10:7422626:G:A | - | 0.0663988156767799 | 0.00322708347309925 | LUAD | Female-baised eQTL |
| rs12355543 | chr10:432245:T:G | - | 0.0780461403600994 | 0.00705902921042594 | LUAD | Female-baised eQTL |
| rs60374183 | chr10:11156167:T:G | - | 0.0484079266235809 | 0.0495335917515758 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs686458 | chr10:14418941:C:T | - | 0.0388940507577411 | 0.00626350852505482 | LUAD | Male-baised eQTL |
| rs2480538 | chr10:14410544:G:A | - | 0.0386165186715358 | 0.00646140712790398 | LUAD | Male-baised eQTL |
| rs634253 | chr10:14412213:T:C | - | 0.0386165186715358 | 0.00646140712790398 | LUAD | Male-baised eQTL |
| rs671858 | chr10:14420314:G:T | - | 0.038729310411389 | 0.00668783920561585 | LUAD | Male-baised eQTL |
| rs689229 | chr10:14419608:G:C | - | 0.0387638324097364 | 0.00673598120444482 | LUAD | Male-baised eQTL |
| rs612931 | chr10:14416337:C:A | - | 0.0380162991913373 | 0.00840357501236954 | LUAD | Male-baised eQTL |
| rs666482 | chr10:14404245:T:A | - | 0.0361053831280188 | 0.0133920123717776 | LUAD | Male-baised eQTL |
| rs649364 | chr10:14405340:T:C | - | 0.035260302129411 | 0.0149361814563057 | LUAD | Male-baised eQTL |
| rs10906666 | chr10:14403730:A:T | - | -0.0326871232471054 | 0.026414976520142 | LUAD | Male-baised eQTL |
| rs1041335 | chr10:14393136:G:C | - | -0.0325187424980094 | 0.0264731627158195 | LUAD | Male-baised eQTL |
| rs10796187 | chr10:14403582:G:C | - | -0.0313581392506938 | 0.0413944503122615 | LUAD | Male-baised eQTL |
| rs78293195 | chr10:14403583:C:G | - | -0.0313581392506938 | 0.0413944503122615 | LUAD | Male-baised eQTL |
| rs662656 | chr10:14378163:T:C | - | 0.0307677729098569 | 0.0457404341219114 | LUAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000178372 |
| CpG Site: cg00797152 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.320658945181318 | |
 | Gene ID: ENSG00000178372 |
| CpG Site: cg02382706 | |
| Position to Gene: gene,exon,promoter,UTR | |
| Male Effect: -0.365476578907404 | |
| Female Effect: - | |
 | Gene ID: ENSG00000178372 |
| CpG Site: cg00797152 | |
| Position to Gene: promoter | |
| Male Effect: -0.365476578907404 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg02382706 | chr10:5498704 | gene,exon,promoter,UTR | -0.365476578907404 | 4.14911344685434e-14 | -0.5332572281407132 | 1.4519047639424045e-17 | STAD |
| cg00797152 | chr10:5499605 | promoter | -0.365476578907404 | 4.14911344685434e-14 | -0.5332572281407132 | 1.4519047639424045e-17 | STAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg00797152 | chr10:5499605 | promoter | -0.320658945181318 | 3.81758541389144e-11 | -0.4497615738256414 | 4.20921094993489e-14 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of CALML5 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
